Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Schott Pharma AG KGaAMIL:1SXP 65 5-Year Yield-on-Cost % is 0.86 as of Aug. 01, 2026, which is 37% above its 10-year median of 0.63. GuruFocus rates MIL:1SXP with a GF Score™ of 65/100 and a GF Value™ of €28.27 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 319 Medical Devices & Instruments companies, Schott Pharma AG KGaA ranks worse than 79.31% on this metric.
Schott Pharma AG KGaA's yield on cost for the quarter that ended in Mar. 2026 was 0.86.
The historical rank and industry rank for Schott Pharma AG KGaA's 5-Year Yield-on-Cost % or its related term are showing as below:
MIL:1SXP'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.38 Med: 0.63 Max: 1.31
Current: 0.86
During the past 6 years, Schott Pharma AG KGaA's highest Yield on Cost was 1.31. The lowest was 0.38. And the median was 0.63.
MIL:1SXP's 5-Year Yield-on-Cost % is ranked worse than 79.31% of 319
companies
in the Medical Devices & Instruments industry
Industry Median: 2.45
vs MIL:1SXP: 0.86
Schott Pharma AG KGaA (MIL:1SXP) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Schott Pharma AG KGaA 5-Year Yield-on-Cost % Related Terms
MIL:1SXP vs ISRG, BDX, MDLN: 5-Year Yield-on-Cost % Comparison
For the Medical Instruments & Supplies subindustry, Schott Pharma AG KGaA's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Schott Pharma AG KGaA 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Schott Pharma AG KGaA's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Schott Pharma AG KGaA's 5-Year Yield-on-Cost % falls into.
Schott Pharma AG KGaA 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Schott Pharma AG KGaA (MIL:1SXP) has a 5-Year Yield-on-Cost % of 0.86 as of Aug. 01, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Schott Pharma AG KGaA and its competitors. This is 37% above median its historical median of 0.63. Over the past decade, Schott Pharma AG KGaA's 5-Year Yield-on-Cost % has ranged from 0.38 to 1.31. According to the industry distribution chart, Schott Pharma AG KGaA ranks #253 out of 319 companies in the Medical Devices & Instruments industry, placing it in the top 79.3%.
Is Schott Pharma AG KGaA's 5-Year Yield-on-Cost % too high?
Schott Pharma AG KGaA's current 5-Year Yield-on-Cost % of 0.86 is 37% above median its 10-year median of 0.63. Over the past 10 years, this metric has ranged from a low of 0.38 to a high of 1.31. The Medical Devices & Instruments industry median 5-Year Yield-on-Cost % is 2.45. Schott Pharma AG KGaA's value of 0.86 is 64.9% below this industry median. Based on the distribution chart, Schott Pharma AG KGaA ranks #253 out of 319 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Schott Pharma AG KGaA has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Schott Pharma AG KGaA's 5-Year Yield-on-Cost % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Schott Pharma AG KGaA ranks #253 out of 319 companies for 5-Year Yield-on-Cost %. This places Schott Pharma AG KGaA in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.45. Schott Pharma AG KGaA's value of 0.86 is 64.9% below this benchmark. Historically, Schott Pharma AG KGaA's own 5-Year Yield-on-Cost % has ranged from 0.38 to 1.31 over the past decade. While the company's 10-year median is 0.63 vs. the industry median of 2.45, Schott Pharma AG KGaA has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.45, based on 319 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Schott Pharma AG KGaA's current 5-Year Yield-on-Cost % of 0.86 is 64.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Schott Pharma AG KGaA and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Schott Pharma AG KGaA's current 5-Year Yield-on-Cost % is 0.86, which is 37% above median its own 10-year median of 0.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Schott Pharma AG KGaA stock overvalued right now?
Based on GuruFocus' analysis, Schott Pharma AG KGaA (MIL:1SXP) is currently considered Modestly Undervalued. The stock's GF Value™ is €28.27, compared to a current price of €21.00 — trading 25.7% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.86, which is 37% above median its 10-year median of 0.63 and 64.9% below the Medical Devices & Instruments industry median of 2.45. Schott Pharma AG KGaA's overall GF Score™ is 65/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Schott Pharma AG KGaA (MIL:1SXP), the current 5-Year Yield-on-Cost % is 0.86 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Schott Pharma AG KGaA (MIL:1SXP) Overvalued in 2026?
Based on GuruFocus' analysis, Schott Pharma AG KGaA stock appears to be undervalued.
The current stock price of €21.00 is trading 25.7% below its estimated GF Value™ of €28.27.
GuruFocus considers Schott Pharma AG KGaA to be Modestly Undervalued.
Key valuation signals for MIL:1SXP:
5-Year Yield-on-Cost %: 0.86 (37% above median its 10-year median of 0.63)
GF Value™: €28.27 vs. price of €21.00 (25.7% below fair value)
Industry Position: 64.9% below the Medical Devices & Instruments median (#253 of 319)
No single metric tells the full story. See the MIL:1SXP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Schott Pharma AG & CO KGaA is an international provider of drug containment solutions and delivery systems for injectable drugs for pharma, biotech and life-sciences. Its business operates in two segments: Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of revenue is being generated from the DCS segment, which includes products like vials, cartridges, and ampoules, and provides customers with sterile and non-sterile options in standard and high-end formats for drug storage. Geographically, the company generates revenue from Europe, the Middle East, Africa (EMEA), Asia and the South Pacific, North America, and South America.
65GF Score
Get the complete analysis for MIL:1SXP
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1SXP has been successfully added to your 
